News | March 14, 2023
Pfizer acquires Seagen for US$ 43 billion to battle cancer
Proposed combination enhances Pfizer’s position as a leading company in oncology
Proposed combination enhances Pfizer’s position as a leading company in oncology
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The cash and debt free consideration value is €370 million.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The scheme is subject to statutory and regulatory approvals as may be necessary.
Post the sale, Patel family has become the single largest promoter shareholder in the company
As a result, Imago will become a subsidiary of Merck.
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Subscribe To Our Newsletter & Stay Updated
